# A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Source: https://onco.cc/trials/nct06667544/  
OnCo record `nct06667544` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RNK08954-01 in sarcomas, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.

## Summary

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation is a phase 1/2 interventional study registered as NCT06667544 by Ranok Therapeutics (Hangzhou) Co., Ltd., with 152 participants planned, started 2024-11-08 and due to reach its primary completion in 2026-12. Interventions recorded: RNK08954-01.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06667544
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of RNK08954 in Patients With Advanced Solid Tumors With a KRAS G12D Mutation TRIAD1 (Trial of RNK08954 In KRAS G12D Mutation)
- Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd.
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT06667544: https://clinicaltrials.gov/study/NCT06667544

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06667544.json